The Goldman Sachs Group Reaffirms "Sell" Rating for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "sell" rating reiterated by research analysts at The Goldman Sachs Group in a research note issued on Friday, Marketbeat Ratings reports. They presently have a $9.00 price objective on the stock. The Goldman Sachs Group's price target would suggest a potential downside of 4.76% from the company's previous close.

Several other equities research analysts also recently weighed in on NTLA. Oppenheimer decreased their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research note on Monday, January 13th. Chardan Capital lifted their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a research note on Monday, November 18th. William Blair reissued a "neutral" rating and set a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. Wells Fargo & Company decreased their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $42.12.

Intellia Therapeutics Stock Down 6.3 %

NTLA traded down $0.64 during midday trading on Friday, hitting $9.45. The company had a trading volume of 2,998,270 shares, compared to its average volume of 3,289,680. Intellia Therapeutics has a 52 week low of $8.96 and a 52 week high of $33.28. The company has a market capitalization of $962.47 million, a price-to-earnings ratio of -1.74 and a beta of 1.80. The stock's 50 day moving average price is $10.85 and its 200 day moving average price is $15.55.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 29,000 shares of company stock worth $352,551 over the last three months. 3.20% of the stock is currently owned by insiders.

Institutional Trading of Intellia Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after purchasing an additional 794 shares during the period. Capstone Investment Advisors LLC raised its position in shares of Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company's stock valued at $1,256,000 after purchasing an additional 831 shares during the period. KBC Group NV raised its position in shares of Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after purchasing an additional 1,020 shares during the period. Axxcess Wealth Management LLC raised its position in shares of Intellia Therapeutics by 5.4% in the third quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company's stock valued at $415,000 after purchasing an additional 1,044 shares during the period. Finally, Ensign Peak Advisors Inc raised its position in shares of Intellia Therapeutics by 2.9% in the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after purchasing an additional 1,100 shares during the period. Institutional investors own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.